The global cell freezing media market size is expected to reach USD 2.37 billion by 2033, registering a CAGR of 9.0% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market is driven by increasing adoption of ready to freezing media, coupled with growing pipeline of biopharmaceuticals leading to a higher demand for these products. In addition, increasing prevalence of chronic disorders, and risen significance of cells therapies in managing them have created traction for effective cell freezing medium.
The growing research and development activities to develop advanced therapies have resulted in increased demand for the cost-effective cryopreservation medium. The ability of ready to use media to reduce the ice crystals formation while cryopreserving viable cells eventually led to its increasing adoption among research community. Furthermore, the increased popularity of biopharmaceuticals due to improved safety and efficacy has cascaded huge investments from manufacturers to develop advanced biopharmaceuticals for life-threatening disorders.
The rapid research and development of COVID-19 vaccine and its continuous commercial production activities has also positively impacted as well as encouraged the biologics-based research activities and eventually boosted the market growth. The increasing market demand, growing competition among players and various application by end users has also attributed to advancements in formulations of cell freezing media and are now even available as per custom requirements. For instance, the Sigma Aldrich brand of Merck KGaA offers freezing media solutions for stem cells application while providing optimal recovery and cells survival.
Rapid advancements in cellular therapy research and growing adoption of cell therapies in various disorders have created a robust demand in the global market. Cell freezing media has a very important role in maintaining functionality of cells during the thawing and freezing process, which is vital for cell therapies applications. In addition, various strategies undertaken by market participants to bolster applications of cellular therapies in managing chronic disorders are projected to accelerate market expansion. For instance, in September 2022, Scribe Therapeutics and Sanofi announced partnership to commercialize CRISPR based therapies for cancer.
Request a free sample copy or view report summary: Cell Freezing Media Market Report
The DMSO (dimethyl sulfoxide) segment dominated the market in 2025 with a revenue share of 71.00% and is attributed to the established gold standard from years of using DMSO in traditional cryopreservation for suspending the metabolic activities of cells.
The stem cells lines segment has the largest application of cell freezing media, whereas cancer cell lines expected to witness fastest growth owing to the increasing clinical success rate of cell and gene therapy products.
Across end use segment, the pharmaceutical and biotechnology companies segment dominated the market with the revenue share of 40.33% in 2025. The higher revenue growth is attributed to the continuous growth and commercial success of biopharmaceuticals coupled with the expanding portfolio of the major pharmaceutical companies.
North America region dominated the global market in 2025, owing to expanding pipeline for biopharmaceuticals, a large pool of key players, rising demand for cell freezing media, and advanced healthcare infrastructure along with developed economy
Grand View Research has segmented the global cell freezing media market based on product, type, cell culture type, application, end use, and region:
Cell Freezing Media Product Outlook (Revenue, USD Million, 2021 - 2033)
DMSO
With Serum
Without Serum
Glycerol
With Serum
Without Serum
Others
Cell Freezing Media Type Outlook (Revenue, USD Million, 2021 - 2033)
Slow Freezing
Vitrification
Cell Freezing Media Cell Culture Type Outlook (Revenue, USD Million, 2021 - 2033)
Suspension Cell Culture
2D Cell Culture
3D Cell Culture
Others
Cell Freezing Media Application Outlook (Revenue, USD Million, 2021 - 2033)
Stem Cells
Mesenchymal Stem Cells (MSCs)
Hematopoietic Stem Cells (HSCs)
Induced Pluripotent Stem Cells (iPSCs)
Embryonic Stem Cells (ESCs)
Others
Cancer Cell Lines
Reproductive Cells
Primary Cells
Bioproduction Cell Lines
CHO Cells
HEK293 Cells
BHK
Others
Others
Cell Freezing Media End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceuticals and Biotechnology Companies
Academic and Research Institutes
Biobanks
Stem Cells
Reproductive Cells
Other Cells
IVF Clinics
Other End Use
Cell Freezing Media Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List Of Key Players Cell Freezing Media Market
Merck KGaA
Sartorius AG
HiMedia Laboratories
Thermo Fisher Scientific Inc.
Bio-Life Solutions, Inc.
Bio-Techne
PromoCell GmbH
Capricorn Scientific
Vitrolife AB
AMSBIO
ZENOGEN PHARMA CO., LTD.
"The quality of research they have done for us has been excellent..."